Trade setup intelligence
Charts, patterns, liquidity, and profile weighting stay together before a setup is surfaced.
Signal through the silt.
Stocks, crypto and news catalysts, ranked into decisions
Follow market prices, charts and current catalysts without an account. When you need a decision workflow, move into ranked intelligence with data-quality checks and risk-aware review.
- Public markets
- Stocks · Crypto · NFTs
- Catalysts
- Source attributed
- Member intelligence
- Risk gated
Automated Market Intelligence
News Catalysts Mixed Directly with Stock Signals
News aggregation engine
Market-moving headlines are normalized, scored, and matched to the stocks they can move.
Automated controls
Automation is gated by data quality, risk limits, and explicit confidence thresholds.
Signal Workflow
Built Around the Decision Path
Ingest
Market headlines and bars enter one data-quality boundary.
Score
Catalysts are separated into bullish, neutral, and bearish context.
Rank
Opportunity boards blend catalyst impact with chart and risk signals.
Control
Execution-facing actions stay behind operator and risk checks.
Current Catalysts
Latest Market Headlines
Source-attributed headlines captured in the last hours, each linked to the public stock and crypto pages it mentions. Browse all market news
Voyager Stock Tanks After Hours — Here's Why
Voyager shares fall after-hours after announcing a $350 million convertible notes offering.
HESM Q2 Beat Masks Lower Volumes as Second-Half Costs Move Higher
Hess Midstream LP (HESM) beat Q2 2026 earnings expectations with 75 cents per share, up 1.4% YoY, despite lower throughput. Higher tariff rates and reduced operating costs offset weaker volumes. Management expects second-half improvement as Chevron wells come online, but Q3 Adjusted EBITDA is projected at $310-320 million as deferred maintenance and capital spending rise. Full-year guidance remains flat versus 2025.
DLTR Lifts 2026 Earnings Outlook as Tariff Refunds Fund Reinvestment
Dollar Tree raised its fiscal 2026 adjusted EPS guidance to $7.70-$8.05, with approximately 60 cents of benefit from tariff refunds. The company plans to reinvest about $210 million of the $383 million tariff refunds received into pricing, marketing, and store operations rather than treating it as a windfall. Q2 results showed net sales increased 7% to $4.89 billion with comparable-store sales rising 3.7%, while the company maintained its full-year sales guidance of $20.5-$20.7 billion.
Why Brinker International Stock Jumped Today
Brinker International (Chili's parent company) stock rose 3.49% after Northcoast upgraded the stock from neutral to buy with a $275 price target, implying 37% upside. The upgrade was driven by strong growth at Chili's, menu improvements, better marketing, and management confidence in achieving in-store margins exceeding 20%. While hypergrowth may be slowing, the company targets 4%-6% annual revenue growth through fiscal 2029 with double-digit adjusted EPS growth.
Where Will SentinelOne (S) Stock Be in 3 Years?
SentinelOne, an AI-powered cybersecurity company, has seen its stock decline from a 2021 high of $76.30 to around $24, trading below its $35 IPO price. While revenue grew from $93M to $1B over five years, growth has decelerated to an expected 20-21% for fiscal 2027, signaling the end of hypergrowth days. The company faces intense competition from larger players like Palo Alto Networks and CrowdStrike, macro headwinds affecting enterprise spending, and declining net revenue retention among enterprise customers. Analysts project modest 18% revenue CAGR through 2029, with the stock potentially reaching $15.4B market cap (86% gain) within three years if current trends hold, but remaining well below its all-time high.
Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight
The global Alzheimer's disease biomarker market is projected to grow from USD 2.2 billion in 2025 to USD 4.7 billion by 2034, driven by rising disease prevalence, aging populations, and advancements in blood-based biomarkers like phosphorylated tau and amyloid-beta assays. North America leads the market with 41% share, while Asia-Pacific is the fastest-growing region. Recent FDA clearances and expanded laboratory testing availability are accelerating market adoption.
Real signals or no signal
The system only ranks opportunities when real market and catalyst data is available. Missing data produces a clear unavailable state instead of noise.
Review integrations